Molecular Basis of Multistep Hepatocarcinogenesis: Genetic and Epigenetic Events

References

• Kim C-M, Koike K, Saito I, Miyamura T, Jay G. HBx gene of hepatitis B virus induces liver cancer in transgenic mice. Nature 1991;351:317–20.
   Google Scholar
• Sakamoto M, Hirohashi S, Shimosato Y. Early stages of multistep hepatocarcinogenesis: adenomatous hyperplasia and early hepatocellular carcinoma. Hum Pathol 1991;22:172–8.
   Google Scholar
• Hirohashi S, Sakamoto M. Hepatocellular carcinoma in the early stage. In: Tobe T, Kameda H, Okudaira M, Ohto M, Endo Y, Mito M, et al., editors. Primary liver cancer in Japan. Tokyo: Springer-Verlag; 1992. p. 25–30.
   Google Scholar
• Tsuda H, Hirohashi S, Shimosato Y, Terada M, Hasegawa H. Clonal origin of atypical adenomatous hyperplasia of the liver and clonal identity with hepatocellular carcinoma. Gastroenterology 1988;95:1664–6.
   Google Scholar
• Kanai T, Hirohashi S, Upton MP, Noguchi M, Kishi K, Makuuchi M, et al. Pathology of small hepatocellular carcinoma: a proposal for a new gross classification. Cancer 1987;60:810–9.
   PubMedGoogle Scholar
• Edmondson AH, Steiner PE. Primary carcinoma of the liver. A study of 100 cases among 48,900 necropsies. Cancer 1954;7: 462–503.
   Google Scholar
• Sakamoto M, Hirohashi S, Tsuda H, Shimosato Y, Makuuchi M, Hosoda Y. Multicentric independent development of hepatocellular carcinoma revealed by analysis of hepatitis B virus integration pattern. Am J Surg Pathol 1989;13:1064–7.
   PubMed Web of Science ®Google Scholar
• Takayama T, Makuuchi M, Hirohashi S, Sakamoto M, Okazaki S, Takayasu K, et al. Malignant transformation of adenomatous hyperplasia to hepatocellular carcinoma. Lancet 1990;336:1150–3.
   PubMedGoogle Scholar
• Robinson WS. Molecular events in the pathogenesis of hepaDNAvirus-associated hepatocellular carcinoma. Annu Rev Med 1994;45:297–323.
   PubMedGoogle Scholar
• Tsuda H, Hirohashi S, Shimosato Y, Ino Y, Yoshida T, Terada M. Low incidence of point mutation of c-Ki-ras and N-ras oncogenes in human hepatocellular carcinoma. Jpn J Cancer Res 1989;80:196–9.
   PubMedGoogle Scholar
• Boix L, Rosa JL, Ventura F, Castells A, Bruix J, Rodes J, et al. c-met mRNA overexpression in human hepatocellular carcinoma. Hepatology 1994;19:88–91.
   PubMed Web of Science ®Google Scholar
• Hollstein M, Sidranksky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 1991;253:49–53.
   PubMed Web of Science ®Google Scholar
• Levine AJ, Momand J, Finlay CA. The p53 tumor suppressor gene. Nature 1991;351: 453–6.
   Google Scholar
• Murakami Y, Hayashi K, Hirohashi S, Sekiya T. Aberrations of the tumor suppressor p53 and retinoblastoma genes in human hepatocellular carcinomas. Cancer Res 1991;51:5520–5.
   PubMed Web of Science ®Google Scholar
• Oda T, Tsuda H, Scarpa A, Sakamoto M, Hirohashi S. p53 gene mutation spectrum in hepatocellular carcinoma. Cancer Res 1992;52: 6358–64.
   Google Scholar
• Oda T, Tsuda H, Sakamoto M, Hirohashi S. Different mutations of the p53 gene in nodule-in-nodule hepatocellular carcinoma as a evidence for multistage progression. Cancer Lett 1994;83:197–200.
   PubMedGoogle Scholar
• Hsu IC, Metcalf RA, Sun T, Welsh JA, Wang NJ, Harris CC. Mutational hotspot in the p53 gene in human hepatocellular carcinomas. Nature 1991;350:427–8.
   PubMed Web of Science ®Google Scholar
• Bressac B, Kew M, Wands J, Ozturk M. Selective G to T mutation of p53 gene in hepatocellular carcinoma from southern Africa. Nature 1991;350:429–31.
   PubMed Web of Science ®Google Scholar
• Zhang X, Xu HJ, Murakami Y, Sachse R, Yashima K, Hirohashi S, et al. Deletions of chromosome 13q, mutations in retinoblastoma 1, and retinoblastoma protein state in human hepatocellular carcinoma. Cancer Res 1994;54:4177–82.
   PubMed Web of Science ®Google Scholar
• Zhang W, Hirohashi S, Tsuda H, Shimosato Y, Yokota J, Terada M, et al. Frequent loss of heterozygosity on chromosomes 16 and 4 in human hepatocellular carcinoma. Jpn J Cancer Res 1990;81:108–11.
   PubMedGoogle Scholar
• Tsuda H, Zhang W, Shimosato Y, Yokota J, Terada M, Sugimura T, et al. Allele loss on chromosome 16 associated with progression of human hepatocellular carcinoma. Proc Natl Acad Sci USA 1990;87:6791–4.
   PubMed Web of Science ®Google Scholar
• Simon D, Knowles BB, Weith A. Abnormalities of chromosome 1 and loss of heterozygosity on 1p in primary hepatomas. Oncogene 1991;6: 765–70.
   Google Scholar
• Konishi M, Kikuchi-Yanoshita R, Tanaka K, Sato C, Tsuruta K, Maeda Y, et al. Genetic changes and histopathological grades in human hepatocellular carcinomas. Jpn J Cancer Res 1993;84:893–9.
   PubMedGoogle Scholar
• Ding S-F, Habib NA, Dooley J, Wood C, Bowles L, Delhanty JDA. Loss of constitutional heterozygosity on chromosome 5q in hepatocellular carcinoma without cirrhosis. Br J Cancer 1991;64: 1083–7.
   Google Scholar
• De Souza AT, Hankins GR, Washington MK, Fine RL, Orton TC, Jirtle RL. Frequent loss of heterozygosity on 6q at the mannose 6-phosphate/insulin-like growth factor II receptor locus in human hepatocellular tumors. Oncogene 1995;10:1725–9.
   PubMedGoogle Scholar
• Emi M, Fujiwara Y, Nakajima T, Tsuchiya E, Tsuda H, Hirohashi S, et al. Frequent loss of heterozygosity for loci on chromosome 8p in hepatocellular carcinoma, colorectal cancer, and lung cancer. Cancer Res 1992;52:5368–76.
   PubMed Web of Science ®Google Scholar
• Emi M, Fujiwara Y, Ohata H, Tsuda H, Hirohashi S, Koike M, et al. Allelic loss at chromosome band 8p21.3-p22 is associated with progression of hepatocellular carcinoma. Genes Chromosomes Cancer 1993;7:152–7.
   PubMed Web of Science ®Google Scholar
• Fujimori M, Tokino T, Hino O, Kitagawa T, Imamura T, Okamoto E, et al. Allelotype study of primary hepatocellular carcinoma. Cancer Res 1991;51:89–93.
   PubMed Web of Science ®Google Scholar
• Takahashi K, Kudo J, Ishibashi H, Hirata Y, Niho Y. Frequent loss of heterozygosity on chromosome 22 in hepatocellular carcinoma. Hepatology 1992;17: 794–9.
   Google Scholar
• Wang HP, Rogler CE. Deletions in human chromosome arms 11p and 13q in primary hepatocellular carcinomas. Cytogenet Cell Genet 1988;48:72–8.
   PubMedGoogle Scholar
• Walker GJ, Hayward NK, Falvey S, Cooksley WGE. Loss of somatic heterozygosity in hepatocellular carcinoma. Cancer Res 1991;51:4367–70.
   PubMed Web of Science ®Google Scholar
• Herman JG, Merlo A, Mao L, Lapidus RG, Issa JPJ, Davidson NE, et al. Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res 1995;55:4525–30.
   PubMed Web of Science ®Google Scholar
• Herman JG, Latif F, Weng Y, Lerman MI, Zbar B, Liu S, et al. Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc Natl Acad Sci USA 1994;91:9700–4.
   PubMed Web of Science ®Google Scholar
• Yoshiura K, Kanai Y, Ochiai A, Shimoyama Y, Sugimura T, Hirohashi S. Silencing of the E-cadherin invasion-suppressor gene by CpG methylation in human carcinomas. Proc Natl Acad Sci USA 1995;92:7416–9.
   PubMed Web of Science ®Google Scholar
• Makos M, Nelkin BD, Lerman MI, Latif F, Zbar B, Baylin SB. Distinct hypermethylation patterns occur at altered chromosome loci in human lung and colon cancer. Proc Natl Acad Sci USA 1992;89:1929–33.
   PubMed Web of Science ®Google Scholar
• Buchagen DL, Qiu L, Etkind P. Homozygous deletion, rearrangement and hypermethylation implicate chromosome region 3p14.3-3p21.3 in sporadic breast-cancer development. Int J Cancer 1994;57: 473–9.
   Google Scholar
• Cheah MSC, Wallace CD, Hoffman RM. Hypomethylation of DNA in human cancer cells: a site-specific change in the c-myc oncogene. J Natl Cancer Inst 1984;73:1057–65.
   Google Scholar
• Vachtenheim J, Horakowa I, Novotna H. Hypomethylation of CCGG sites in the 3′ region of H-ras protooncogene is frequent and is associated with H-Ras allele loss in non-small cell lung cancer. Cancer Res 1994;54: 1145–8.
   Google Scholar
• Cedar H, Razin A. DNA methylation and development. Biochem Biophys Acta 1990;1049:1–8.
   PubMedGoogle Scholar
• El-Deiry WS, Nelkin BD, Celano P, Yen R-W, Falco JP, Hamilton SR, et al. High expression of the DNA methyltransferase gene characterizes human neoplastic cells and progression atages of colon cancer. Proc Natl Acad Sci USA 1991;88: 3470–4.
   Google Scholar
• Issa J-P, Vertino PM, Wu J, Sazawal S, Celano P, Nelkin BD, et al. Increased cytosine DNA-methyltransferase activity during colon cancer progression. J Natl Cancer Inst 1993;85:1235–40.
   PubMed Web of Science ®Google Scholar
• Wu J, Issa J-P, Herman J, Bassett DE, Nelkin BD, Baylin SB. Expression of an exogenous eukaryotic DNA methytransferase gene induces transformation of NIH 3T3 cells. Proc Natl Acad Sci USA 1993;90: 8891–5.
   Google Scholar
• MacLeod AR, Szyf M. Expression of antisense to DNA methytransferase mRNA induces DNA methylation and inhibits tumorigenesis. J Biol Chem 1995;270:8037–43.
   PubMed Web of Science ®Google Scholar
• Ramchandani S, MacLeod AR, Pinard M, von Hofe E, Szyf M. Inhibition of tumorigenesis by a cytosine DNA, methyltransferase, antisense oligodeoxynucleotide. Proc Natl Acad Sci USA 1997;94:684–9.
   PubMed Web of Science ®Google Scholar
• Laid PW, Laurie J-G, Fazeli A, Dickinson SL, Jung WE, Li E, et al. Suppression of intestinal neoplasia by DNA hypomethylation. Cell 1995;81:197–205.
   Google Scholar
• Sun L, Hui A-M, Kanai Y, Sakamoto M, Hirohashi S. Increased DNA methyltransferase expression is associated with an early stage of human hepatocarcinogenesis. Jpn J Cancer Res 1998;88:1165–70.
   Google Scholar
• Sasaki T, Toguchida J, Ohtani N, Yandell DW, Rapaport JM, Dryja TP. Allele-specific hypermethylation of the retinoblastoma tumor-suppression gene. Am J Hum Genet 1991;48:880–8.
   PubMedGoogle Scholar
• Wales MM, Bile MA, El Deiry W, Nelkin BD, Issa J-P, Cavenee WK, et al. p53 activates expression of HIC-1, a new candidate tumor suppressor gene on 17p13.3. Nat Med 1995;1: 570–7.
   Google Scholar
• Kanai Y, Hui A-M, Sun L, Ushijima S, Sakamoto M, Tsuda H, et al. DNA hypermethylation at the D17S5 locus and reduced HIC-1 mRNA expression are associated with hepatocarcinogenesis. Hepatology 1999;29: 703–9.
   Google Scholar
• Makos M, Nelkin B, Reiter RE, Gnarra JR, Brooks J, Issacs W, et al. Regional DNA hypermethylation at D17S5 precedes 17p structural changes in the progression of renal tumors. Cancer Res 1993;53:2719–22.
   PubMedGoogle Scholar
• Pieretti M, Powell DE, Gallion HH, Conway PS, Case EA, Turker MS. Hypermethylation at a chromosome 17 ‘hot spot’ is a common event in ovarian cancer. Hum Pathol 1995;26:398–401.
   PubMedGoogle Scholar
• Kanai Y, Ushijima S, Tsuda H, Sakamoto M, Sugimura T, Hirohashi S. Aberrant DNA methylation on chromosome 16 is an early event in hepatocarcinogenesis. Jpn J Cancer Res 1996;87:1210–7.
   PubMedGoogle Scholar
• Yang AS, Shen J-C, Zingg J-M, Mi S, Jones PA. Hha I and Hpa II DNA methyltransferase bind DNA mismatches, methylate uracil and block DNA repair. Nucleic Acids Res 1995;23:1380–7.
   Google Scholar
• Shen J-C, Rideout III WM, Jones PA. High frequency mutagenesis by a DNA methyltransferase. Cell 1992;71:1073–80.
   Google Scholar
• Hunter T, Pines J. Cyclins and cancer. II. Cyclin D and CDK inhibitors come of age. Cell 1994;79:573–82.
   Google Scholar
• Peter M, Herskowitz I. Joining the complex: cyclin-dependent kinase inhibitory proteins and the cell cycle. Cell 1994;79:181–4.
   PubMed Web of Science ®Google Scholar
• Cairns P, Polascik TJ, Eby Y, Tokino K, Califano J, Merlo A, et al. Frequency of homozygous deletion at p16/CDKN2 in primary human tumours. Nat Genet 1995;11:210–2.
   PubMed Web of Science ®Google Scholar
• Hussussian CJ, Ptruewing JP, Goldstein AM, Higgins PAT, Ally DS, Sheahan MD, et al. Germline p16 mutations in familial melanoma. Nat Genet 1994;8:15–21.
   PubMed Web of Science ®Google Scholar
• Mori T, Miura K, Aoki T, Nishihira T, Mori S, Nakamura Y. Frequent somatic mutation of the MTS1/CDK4I (multiple tumor suppressor/cyclin-dependent kinase 4 inhibitor) gene in esophageal squamous cell carcinoma. Cancer Res 1994;54:3396–7.
   PubMed Web of Science ®Google Scholar
• Hui A-M, Sakamoto M, Kanai Y, Ino Y, Gotoh M, Yokota J, et al. Inactivation of p16INK4 in hepatocellular carcinoma. Hepatology 1996;24: 575–9.
   Google Scholar
• Hui A-M, Kanai Y, Sakamoto M, Tsuda H, Hirohashi S. Reduced p21WAF1/CIP1 expression and p53 mutation in hepatocellular carcinomas. Hepatology 1997;25: 575–9.
   Google Scholar
• Hui A-M, Sun L, Kanai Y, Sakamoto M, Hirohashi S. Reduced p27Kip1 expression in hepatocellular carcinomas. Cancer Lett 1998;132: 67–73.
   Google Scholar
• Nishida N, Fukuda Y, Komeda T, Kita R, Sando T, Fukukawa M, et al. Amplification and overexpression of the cyclin D1 gene in aggressive human hepatocellular carcinoma. Cancer Res 1994;54:3107–10.
   PubMed Web of Science ®Google Scholar
• Hui A-M, Sakamoto M, Kanai Y, Ino Y, Gotoh M, Hirohashi S. Cyclin-dependent kinase inhibitors and hepatocarcinogenesis. In: Tahara E, Sugimachi K, Oohara T, editors. Recent advances in gastroenterological carcinogenesis. Bologna: Monduzzi Editore; 1996. p. 481–5.
   Google Scholar
• Hui A-M, Makuuchi M, Li X. Cell cycle regulators and human hepatocarcinogenesis. Hepatogastroenterology 1998;45:1635–42.
   PubMedGoogle Scholar